Elevance Health Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Elevance Health Bundle
Download Your Competitive Advantage
Quick look: Elevance Health’s BCG Matrix teases which business lines are scaling like Stars, which are steady Cash Cows, and which need a rethink. This preview gives you the framing — but the full BCG Matrix delivers quadrant-by-quadrant placement, data-backed recommendations, and strategic moves tied to real market dynamics. Purchase the complete report for a ready-to-present Word analysis plus an Excel summary, and get the clarity you need to allocate capital and act fast.
Stars
Medicare Advantage
Elevance Health's Medicare Advantage franchise is a Star: roughly 6.8 million MA members in 2024 and high enrollment momentum in a market that grew about 7% YoY in 2024 place it in high-share, high-growth territory. It generates strong cash flow but requires ongoing spend on benefits, broker commissions, and medical management. Continued investment is necessary to defend and grow share as competitors scale into MA.
Medicaid managed care (expansion states)
Medicaid managed care in expansion states is a star: states continue to rebid and broaden populations, driving sustained enrollment growth, and contracts often exceed $1 billion with tens–hundreds of millions in capital required. Elevance’s scale and deep care-management capabilities give it leadership in multiple markets, supporting retention and renewal. The upside is real—hold share, win renewals, and double down on quality scores to secure long-term margins.
Carelon Pharmacy (PBM)
Carelon Pharmacy (PBM) sits in the BCG Stars quadrant as rising pharmacy spend fuels integrated PBM growth; IQVIA 2024 shows global medicine spending near 1.6 trillion. Elevance’s PBM holds significant book and strategic weight, making it a market leader with elevated growth. It needs ongoing investment in rebate strategy, specialty and clinical programs to convert into outsized cash as growth normalizes.
Behavioral health integration
Behavioral health integration is a Star for Elevance: US mental health prevalence is about 1 in 5 adults, and Elevance serves roughly 48 million medical members (2023 filings), so integrated behavioral+medical care drives better outcomes and differentiation—supporting growth and share. Scaling requires network build‑out, digital tools, and access expansion; funding this lifts retention and premiums.
- Demand: 1 in 5 adults
- Reach: ~48M members (2023)
- Invest: network, digital, access → retention & premium lift
Value‑based care arrangements
Provider risk‑sharing is scaling rapidly; Elevance reported over $160 billion in 2024 revenue and has expanded value‑based arrangements into double‑digit millions of lives, positioning this as a high‑growth, high‑influence Stars lane.
Elevance’s claims, clinical and social‑determinants data give it leverage to lead; standing up enablement and advanced analytics requires upfront investment but yields strategic margin and network control.
Invest now to lock advantage before market maturation; payoffs include higher medical loss ratio discipline and deeper provider partnerships driving durable share gains.
- Revenue 2024: >160 billion (Elevance)
- Value‑based lives: double‑digit millions
- Strategic ROI: higher margin, better MLR control
MA scale 6.8M, PBM reach $1.6T market
Elevance’s Medicare Advantage (6.8M members in 2024) and Medicaid expansion contracts (> $1B) are Stars, driving high share in a ~7% YoY MA market (2024). Carelon PBM taps $1.6T global medicine spend (IQVIA 2024) but needs investment to monetize. Behavioral integration (~48M medical members, 2023) and value‑based lives (double‑digit millions) require capex to secure margins.
| Metric | 2023/24 Value |
|---|---|
| MA members | 6.8M (2024) |
| Elevance revenue | >$160B (2024) |
| Global med spend | $1.6T (IQVIA 2024) |
| Medical members | ~48M (2023) |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix of Elevance Health, mapping Stars, Cash Cows, Question Marks, Dogs with strategic invest/hold/divest guidance.
Customizable Excel Spreadsheet
One-page Elevance Health BCG Matrix placing each business unit in a quadrant to cut debate and speed C-suite decisions.
Cash Cows
Commercial group (fully insured)
Commercial group (fully insured) sits in a mature employer market with stable share in core geographies and limited organic growth (US employer market growth ~1.5% in 2024). Predictable margins when priced and managed tightly — underwriting discipline, network management and utilization controls drive consistent profitability. Lower incremental promotional spend needed; focus is retention and risk selection. Acts as cash-generating franchise to fund growth while protecting key accounts.
Administrative services only (ASO)
Elevance Healths ASO business sits squarely in Cash Cows: a large, sticky client base buying administration plus network services, supporting roughly 46 million covered lives in 2024 and commanding high share in employer-administered plans while operating in a low-growth market. Fee revenue is steady with limited capital intensity, producing predictable cash flow and allowing efficiency gains to drop to the bottom line. Priority: maintain service quality and upsell care management to sustain margins and extend lifetime value of clients.
PPO network access
Elevance leverages established Blue networks within a Blue Cross Blue Shield system that served over 106 million members in 2024, giving durable demand and high switching costs that preserve membership (Elevance medical membership ~48 million in 2024). Market growth is flat but share remains strong, so minimal promotion beyond account management is needed. Focus on optimized pricing and tightened utilization controls to sustain cash generation.
Care management programs
Care management programs are cash cows: chronic condition and utilization management are mainstream and Elevance runs them at scale with proven ROI; 2024 revenue $173.7B and ~48M members underpin scale. Mature but profitable, incremental investment focuses on automation and targeting to squeeze efficiency while keeping outcomes stable (10–15% fewer hospitalizations; ~$300 annual savings per high‑risk member).
- Scale: 2024 revenue 173.7B; ~48M members
- Impact: 10–15% fewer admissions
- ROI: ≈$300 annual saving per high‑risk member
- Focus: automation, targeted outreach, efficiency
Ancillary: dental, vision, life add‑ons
Ancillary: dental, vision, life add‑ons ride Elevance Health’s core medical sale, capturing high share inside a ~48 million member book (2024); category is slow growth but low capex with dependable incremental margins, bundling sustains retention and lifts ARPU—keep packaging simple, price for margin, avoid over‑engineering.
- High attachment, low capex
- Slow growth, steady margins
- Bundling = retention + ARPU
- Simple packaging, margin pricing
Growth 1.5%, ASO 46M, care saves $300
Commercial fully insured stable in 2024 US employer growth ~1.5%, delivers predictable underwriting margins and funds growth.
ASO supports ~46M covered lives in 2024, low growth, high stickiness, steady fee cash flow and low capex.
Care management scale (2024 revenue 173.7B; ~48M members) cuts admissions 10–15% with ≈$300 annual saving per high‑risk member.
| Metric | 2024 |
|---|---|
| Revenue | 173.7B |
| Members | ~48M |
| ASO covered lives | ~46M |
| BCBS system reach | ~106M |
| Admissions reduction | 10–15% |
| Savings/high‑risk | ~$300 |
Delivered as Shown
Elevance Health BCG Matrix
The file you're previewing here is the exact Elevance Health BCG Matrix you'll receive after purchase — no watermarks, no demo fluff, just the finished, fully formatted report. It's built for strategic clarity and ready to drop into presentations or planning sessions. Once bought, the full document is sent to your inbox and is immediately editable. No surprises, no extra steps — just a clean, professional deliverable.
Dogs
Legacy small‑group PPO blocks
Legacy small-group PPO blocks are classic Dogs: low market growth and annual churn often exceeds 25%, with price sensitivity eroding share and margins. Administrative complexity per member is materially higher than for modern book segments, driving SG&A burdens that compress returns. Turnarounds in these pockets rarely pay off; prudent action is to prune exposures or reprice aggressively to restore economics.
Under‑scale HMOs in fringe geographies
Under‑scale HMOs in fringe geographies leave Elevance with low share and minimal provider leverage, eroding thin margins; these pockets contrast with Elevance serving roughly 48 million members in 2024, showing density gaps. They tie up capital and management attention while delivering limited growth. Consider exit or folding these HMOs into broader regional products to redeploy resources.
Standalone wellness apps (non‑integrated)
Standalone wellness apps without clinical or claims integration are nice‑to‑have but rarely move the needle: real‑world programs report active user rates often under 15% at 90 days and minimal impact on utilization metrics. Low adoption, low differentiation and low growth mean cash trickles out in upkeep (maintenance often consumes 1–3% of product budgets). Sunset these or integrate tightly into care pathways only if ROI is provable.
Outdated point solutions with overlapping vendors
Outdated point solutions with overlapping vendors drain value through legacy contracts that duplicate core platform capabilities; by 2024 these modules show minimal adoption, no defensible moat and limited renewal momentum. They neither grow nor contribute meaningful cash and act as maintenance liabilities; consolidate and decommission to free capital and reduce vendor complexity.
- Action: consolidate vendors
- Target: decommission low-adoption modules
- Metric: track ARR erosion and TCO
Micro‑market exchange offerings with chronic losses
Micro‑market exchange offerings in select counties have failed to scale, leaving market share low while local markets show stagnant enrollment and premium growth; pricing resets have not repaired unit economics and loss ratios remain chronic, making continued investment uneconomical. Exit and redeploy capital to higher‑growth, defensible segments within Elevance Health.
- Tag: low share
- Tag: stagnant market
- Tag: negative unit economics
- Tag: exit & redeploy
Prune low-adoption PPOs, fringe HMOs and wellness apps — cut churn and consolidate
Legacy small‑group PPOs, under‑scale HMOs, standalone wellness apps and legacy point solutions are Dogs: low growth, high churn (annual churn >25%) and thin margins versus Elevance’s ~48 million members in 2024. Low adoption (<15% at 90 days) and maintenance (1–3% of product budgets) justify pruning, consolidation or exit.
| Segment | 2024 | Key metric | Action |
|---|---|---|---|
| Small‑group PPO | — | Churn >25% | Prune/reprice |
| Fringe HMO | Density gap vs 48M | Low share | Exit/fold |
| Wellness apps | — | Active <15% | Sunset/integrate |
Question Marks
ACA Individual exchange expansion
The ACA individual exchange market is growing—CMS reported roughly 14.6 million plan selections for 2024—but competition is intense and highly regional.
In newer or re‑entry geographies Elevance often starts with low share and materially higher customer acquisition costs, making early density expensive.
With the right provider networks and differentiated benefits an exchange line can scale into a Star; leadership must decide quickly whether to invest for regional density or pull back.
Virtual primary care
Virtual primary care utilization remains elevated versus pre‑pandemic, with virtual visits making up roughly 10–20% of outpatient primary care in 2024.
As a Question Mark, winner‑take‑most dynamics aren’t fixed: Elevance has assets and about 48 million members (2024) plus analytics and provider networks, but needs scale, habit formation, and integration to capture share.
Early returns can appear thin as unit economics improve only after enrollment density and repeated use; go big on integrated navigation or partner and limit spend.
Home‑based care and post‑acute enablement
Home-based care and post-acute enablement benefit from clear tailwinds: the US 65+ population is about 56 million (2024) and Medicare Advantage penetration exceeds 50% of beneficiaries, driving cost shifts out of facilities. Share is patchy and operational complexity—networking, logistics, workforce—is real. If Elevance builds reliable provider networks and logistics, this can flip to a Star. Test, prove outcomes at scale before broad roll-out.
Specialty pharmacy (rare/ultra‑rare)
Specialty pharmacy (rare/ultra-rare) sits in Question Marks for Elevance: an exploding late‑stage gene and cell therapy pipeline in 2024 meets hard access, distribution, and outcomes‑contracting challenges. Current share varies significantly by therapeutic area, and heavy investment is required in capabilities and patient services. Bet selectively where network strength translates to wins.
- High per‑patient cost pressures (launches often >$250k/year)
- Growing late‑stage pipeline in 2024 increases upside
- Access and outcomes contracts remain execution risks
- Invest selectively where care coordination yields measurable market share
Data/AI analytics products for employers
Market interest in Data/AI analytics products for employers is high but fragmented, with many point players competing for share; Elevance’s access to claims and clinical data across over 50 million members in 2024 is a clear advantage, yet converting that into paid products remains the main hurdle. Early revenue from pilots has been modest versus build and integration costs, so prioritize validating use cases that deliver measurable savings before scaling.
- High demand, crowded market
- Data advantage: >50M members (2024)
- Conversion hurdle: data→paid product
- Early revenue < build costs
- Strategy: validate ROI-driving use cases, then scale
14.6M ACA selections, 48M+ members — density, virtual care & selective AI bets
Elevance faces several Question Marks: ACA exchanges (14.6M selections in 2024) and newer geographies need rapid density to reach profitable unit economics; virtual primary care (10–20% of visits in 2024) and home/post‑acute care can scale if networks/logistics prove out; specialty pharmacy and Data/AI need selective investment given >48M members and high upfront costs.
| Area | 2024 metric | Key decision |
|---|---|---|
| ACA exchanges | 14.6M selections | Invest for density? |
| Members/data | 48M+ | Monetize selectively |
| 65+ market | 56M; MA>50% | Scale home care |